BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8730015)

  • 1. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Hodson ME
    Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.
    Costello CM; O'Connor CM; Finlay GA; Shiels P; FitzGerald MX; Hayes JP
    Thorax; 1996 Jun; 51(6):619-23. PubMed ID: 8693445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
    Hansen G; Hoffjan S; Mosler K; Schuster A
    Lung; 2001; 179(3):185-94. PubMed ID: 11891608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
    Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
    Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
    Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
    Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
    Griese M; App EM; Duroux A; Burkert A; Schams A
    Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice.
    Cantin AM
    Am J Respir Crit Care Med; 1998 Feb; 157(2):464-9. PubMed ID: 9476859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum.
    Rochat T; Pastore FD; Schlegel-Haueter SE; Filthuth I; Auckenthaler R; Belli D; Suter S
    Eur Respir J; 1996 Nov; 9(11):2200-6. PubMed ID: 8947060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
    Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
    Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
    Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
    Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
    Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro.
    Dasgupta B; Tomkiewicz RP; Boyd WA; Brown NE; King M
    Pediatr Pulmonol; 1995 Aug; 20(2):78-82. PubMed ID: 8570306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of recombinant human DNase in cystic fibrosis patients.
    Aitken ML
    Monaldi Arch Chest Dis; 1993 Dec; 48(6):653-6. PubMed ID: 8124306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New pharmacological approaches: rhDNase].
    Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
    Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
    Shak S; Capon DJ; Hellmiss R; Marsters SA; Baker CL
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9188-92. PubMed ID: 2251263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients.
    Heijerman HG; van Rossem RN; Bakker W
    Neth J Med; 1995 Jun; 46(6):293-7. PubMed ID: 7643945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.